Alliqua BioMedical Stock Company Profile

Description

Alliqua BioMedical, Inc. provides wound care solutions in the United States and internationally. The company offers the MIST Therapy system for the treatment of acute and chronic wounds; Extracellular Matrix, a suite of advanced wound management products; Biovance, a decellularized and dehydrated allograft for the management of non-infected partial-and full-thickness wounds; SilverSeal, a hydrogel wound dressing with silver coated fibers; connective tissue matrix (CTM) products; and Hydress, an over-the-counter hydrogel wound dressing. It also provides contact dressings, island dressings, and wraps using TheraBond 3D antimicrobial barrier systems. In addition, the company offers Sorbion sachet S, a primary dressing for exudating wounds, such as surgical wounds, venous leg ulcers, and diabetic ulcers; Sorbion sana, a primary wound dressing that provides an another form of wound treatment; and products with hydrokinetic fibers as primary dressings. Further, it provides contract manufacturing services, including the development, manufacture, and market of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company has a license, marketing, development, and supply agreement with Anthrogenesis Corporation to develop and market Extracellular Matrix, Biovance, and CTM products. Alliqua BioMedical, Inc. primarily serves medical device manufacturers through independent network of agents. The company is headquartered in Yardley, Pennsylvania.